<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2477</td>
<td>Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance</td>
<td>Enrique Rozengurt, Heloisa P. Soares, and James Sinnet-Smith</td>
</tr>
<tr>
<td>2489</td>
<td>Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma</td>
<td>Diana Cirstea, Loredana Santo, Teru Hideshima, Homare Eda, Yuko Mishima, Neeharika Nemani, Anuj Mahindra, Andrew Yee, Gullu Gorgun, Yiguo Hu, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M. Guichard, Kenneth C. Anderson, and Noopur Raje</td>
</tr>
<tr>
<td>2501</td>
<td>Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer</td>
<td>Francis W. Hunter, Huai-Ling Hsu, Jiechuang Su, Susan M. Pullen, William R. Wilson, and Jinli Wang</td>
</tr>
<tr>
<td>2515</td>
<td>Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer</td>
<td>Mary Ellen Molloy, Bethany E. Perez White, Teshome Gherezghiher, Bradley T. Michalsen, Rui Xiong, William R. Wilson, and Jingli Wang</td>
</tr>
<tr>
<td>2527</td>
<td>Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification</td>
<td>Seung Tae Kim, Hye-Lim Jang, Su Jin Lee, Jeeyun Lee, Yoon-La Choi, Kyoung-Mee Kim, Jeonghee Cho, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Masakazu Yashiro, Won Ki Kang, and Joon Oh Park</td>
</tr>
<tr>
<td>2547</td>
<td>The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CHS183284/Debio 1347, a Novel Selective FGFR Inhibitor</td>
<td>Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi, Toshihiko Fujii, Kiyoaki Sakata, Hitoshi Sase, Takehito Isobe, Kenji Morikami, Hidetoshi Shindoh, Toshiyuki Mio, Hirosato Ebike, Naoki Taka, Yoko Aoki, and Nobuya Ishii</td>
</tr>
<tr>
<td>2559</td>
<td>Monensin Inhibits Epidermal Growth Factor Receptor Trafficking and Activation: Synergistic Cytotoxicity in Combination with EGFR Inhibitors</td>
<td>Khalil Dayekh, Stephanie Johnson-Obaseki, Martin Corsten, Patrick J. Villeneuve, Harmanjatinder S. Sekhon, Johanne I. Weberpals, and Jim Dimitrulakos</td>
</tr>
<tr>
<td>2572</td>
<td>Targeted Silencing of MLL5 Inhibits Tumor Growth and Promotes Gamma-Irradiation Sensitization in HPV16/18-Associated Cervical Cancers</td>
<td>Dawn Sijin Nin, Chow Wenn Yew, Sun Kuie Tay, and Lih-Wen Deng</td>
</tr>
<tr>
<td>2595</td>
<td>Development of Targeted Near-Infrared Imaging Agents for Prostate Cancer</td>
<td>Xinning Wang, Steve S. Huang, Warren D.W. Heston, Hong Guo, Bing-Cheng Wang, and James P. Basilion</td>
</tr>
</tbody>
</table>
2607  Anti-MET ImmunoPET for Non–Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments
Keyu Li, Richard Tavare, Kirstin A. Zettlitz, Shannon M. Mumenthaler, Parag Mallick, Yu Zhou, James D. Marks, and Anna M. Wu

2618  Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
Wim Dokter, Ruud Ubink, Miranda van der Lee, Monique van der Vleuten, Tanja van Achterberg, Danielle Jacobs, Eline Loosveld, Ellen Mattaar, Patrick Groothuis, Patrick Beusker, Ruud Coumans, Ronald Elgersma, Tijl Huijbregts, Vincent de Groot, Michel Eppink, Guy de Roo, Gijs Verheijden, and Marco Timmers

2630  An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models

2641  A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor Activity
Thomas List, Giulio Casi, and Dario Neri

2653  Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Christine Alewine, Laiman Xiang, Takao Yamori, Gerhard Niederfellner, Klaus Bosslet, and Ira Pastan

2662  MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas
Haihong Zhong, Christine Fazenbaker, Shannon Breen, Cui Chen, Jiaqi Huang, Christopher Morehouse, Yihong Yao, and Robert E. Hollingsworth

2674  Therapeutic Targeting of Angiogenesis with a Recombinant CTT Peptide–Endostatin Mimic–Kringle 5 Protein
Houbin Wang, Zhigang Yang, and Jun Gu

2688  Development of Human Serine Protease-Based Therapeutics Targeting Fn14 and Identification of Fn14 as a New Target Overexpressed in TNBC
Hong Zhou, Khalid A. Mohamedali, Ana Maria Gonzalez-Angulo, Yu Cao, Mary Migliorini, Lawrence H. Cheung, Janine LoBello, Xiudong Lei, Yuan Qi, Walter N. Hittelman, Jeffrey A. Winkles, Nhan L. Tran, and Michael G. Rosenblum

2706  Longitudinal Time-Dependent Effects of Irradiation on Multidrug Resistance in a Non–Small Lung Cancer Cell Line
Yumiko Kono, Keita Utsumi, Shohi Kanno, and Noboru Tanigawa

2713  SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression
Victoria J. Findlay, Cindy Wang, Lourdes M. Nogueira, Katie Hurst, Daniel Quirk, Stephen P. Ethier, Kevin F. Staveley O’Carroll, Dennis K. Watson, and E. Ramsay Camp

2727  Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts
Alastair H. Kyle, Jennifer H.E. Baker, Maria-Jose Gandolfo, Stefan A. Reinsberg, and Andrew I. Minchinton

2738  A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma
Tuhina Mazumdar, Lauren A. Byers, Patrick Kwok Shing Ng, Gordon B. Mills, Shaohua Peng, Lixia Diao, You-Hong Fan, Katherine Stemke-Hale, John V. Heymach, Jeffrey N. Myers, Bonnie S. Glisson, and Faye M. Johnson

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS
MODELS AND TECHNOLOGIES

2751 Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Manuela Gridling, Scott B. Ficarro, Florian P. Breitwieser, Lanxi Song, Katja Parapatics, Jacques Colinge, Eric B. Haura, Jarrod A. Marto, Giulio Superti-Furga, Keiryn L. Bennett, and Uwe Rix

LETTERS TO THE EDITOR

2763 PDT with a Glucose-Conjugated Chlorin for GIST—Letter
Mark Linch and Andrew J. Hayes

2764 PDT with a Glucose-Conjugated Chlorin for GIST—Response
Hiromi Kataoka and Mamoru Tanaka

CORRECTION

2765 Correction: The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells

ABOUT THE COVER

Interrelation between vasculature, blood flow, proliferation, and hypoxia is shown in an HCT116 tumor xenograft 24 hours following irinotecan treatment. Irinotecan initially halts proliferation throughout the tissue but by 24 hours the S-phase fraction returns to near-control levels. The image was produced using multiplexed immunohistochemistry to illustrate the effects of drugs in the context of the tumor microenvironment. Greyscale images of the individual staining patterns were coregistered to produce the composite image shown here. HCT116 xenografts exhibit a corded architecture, where sheaths of tumor cells can be seen to surround individual vessels. Cells can survive to ~150 m away from the blood vessels but become increasingly oxygen-deprived and eventually necrose. For details, see the article by Kyle and colleagues on page 2727.
Molecular Cancer Therapeutics

13 (11)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/13/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/13/11. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.